Business
Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.
PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics,
About this update from Scilex Holding Company
[{"type":"text","content":"PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it will be presenting data on ELYXYB™ (celecoxib oral solution) for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society (AHS) to be held on June 14-18, 2023 in Austin, Texas. An industry-sponsored symposium entitled “ELYXYB: A Fast Acting Oral Solution for Acute Migraine” will be held on Friday, June 16, 2023 from 7:00AM – 7:45 AM CST. Stuart J. Tepper, MD, FAHS from Dartmouth-Hitchcock Medical Center will be presenting clinical trial data from the ELYXYB pivotal studies. A poster entitled “Detection and Adjustment for Participant Response Effects in a 2-Period, Randomized, Double-Blind, Placebo-Controlled Trial of Celecoxib Oral Solution for the Acute Treatment of Migraine” will be presented on Saturday, June 17 from 12:45 – 2:00 PM CST. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex submitted a request to the FDA for a type C meeting for purposes of pre-NDA discussion with the FDA. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product ZTlido® in October 2018, in-licensed a commercial product Gloperba® in June 2022, and launched its third FDA-approved product ElyxybTM in April 2023. It is also developing its late-stage pipeline, which includes...